Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Sorafenib Oral Suspension vs Marketed Tablet
NCT02538393Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer (4 arms), sponsored by Bayer. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Last Data Point and Maximum Observed Drug Concentration. Started Nov 2015; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)thyroid cancer
Beyond the preview
Go deeper on NCT02538393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538393.